Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
Source: SeekingAlpha
2025-09-25 22:53:49 ET
Introduction
Rigel Pharmaceuticals (RIGL) is a commercial-stage biotechnology company that is developing oral small-molecule kinase inhibitors, which are used to help treat blood disorders and certain cancers. Despite having three commercialized products and margins significantly above peers, the market continues to value Rigel as if it were a single-asset, high-risk biotechnology company....
Read the full article on Seeking Alpha
For further details see:
Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
Rigel Pharmaceuticals Inc.
NASDAQ: RIGL
RIGL Trading
-3.13% G/L:
$26.0825 Last:
96,605 Volume:
$26.87 Open:
RIGL Latest News
March 03, 2026 04:01:00 pm
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
RIGL Stock Data
$625,132,287
16,430,597
0.07%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
